Get the Stockscreener App
0.042
0.86%
-0.0045
Galera Therapeutics Inc stock is traded at $0.042, with a volume of 142.78K.
It is down -0.86% in the last 24 hours and down -43.95% over the past month.
See More
Previous Close:
$0.0465
Open:
$0.0431
24h Volume:
142.78K
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-69.68M
P/E Ratio:
-0.0222
EPS:
-1.89
Net Cash Flow:
$-48.93M
1W Performance:
-0.86%
1M Performance:
-43.95%
6M Performance:
-23.49%
1Y Performance:
-96.95%
1-Day Range:
$0.042
$0.046
1-Week Range:
$0.042
$0.046
52-Week Range:
$0.042
$0.046
Galera Therapeutics Inc Stock (GRTX) Company Profile
Name
Galera Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare GRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRTX
Galera Therapeutics Inc
|
0.042 | 0 | 0 | -69.68M | -48.93M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-10-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-19-21 | Downgrade | BofA Securities | Buy → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-16-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Dec-02-19 | Initiated | BTIG Research | Buy |
| Dec-02-19 | Initiated | BofA/Merrill | Buy |
| Dec-02-19 | Initiated | Citigroup | Buy |
| Dec-02-19 | Initiated | Credit Suisse | Neutral |
View All
Galera Therapeutics Inc Stock (GRTX) Latest News
Galera Therapeutics Acquires Nova Pharmaceuticals to Advance Breast Cancer Treatment - MSN
Windtree Therapeutics Unveils New Strategy to Drive Revenue Growth - MyChesCo
Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - MSN
Immedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million Deal - MyChesCo
Galera Therapeutics director Nancy Chang buys $499,978 in stock By Investing.com - Investing.com South Africa
St. Louis-born Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Galera Therapeutics director Nancy Chang buys $499,978 in stock - Investing.com
Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech
Galera Therapeutics Completes Nova Pharmaceuticals Acquisition - citybiz
Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Galera Therapeutics Expands with Nova Pharmaceuticals Acquisition - TipRanks
Oncotelic Therapeutics Implements PDAOAI Platform - The Manila Times
Galera Therapeutics completes acquisition of Nova Pharmaceuticals - The Bakersfield Californian
Galera Therapeutics Acquires Nova Pharma, Pivots to Breast Cancer Drug Development with $3M Investment - StockTitan
Galera Therapeutics, Inc. acquired Nova Pharmaceuticals, Inc. - Marketscreener.com
Guardian Capital Partners Acquires Team LINX to Drive Growth in Technology Infrastructure - MyChesCo
Twelve option delistings on December 23rd - TipRanks
Layoff Tracker: Stubborn Layoff Trend Continues Across Biopharma in 2024 - BioSpace
FDA Tracker: FDA Hands Out Atopic Dermatitis Approvals to Galderma, Organon - BioSpace
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MyChesCo
Radiation Induced Esophagitis Market Set to Grow Substantially Through 2032, DelveInsight Projects | Galera Therapeutics - The Globe and Mail
Galera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Galera Therapeutics Inc. (GRTX) reports earnings - Quartz
Verrica Pharmaceuticals Grants Stock Option to New COO David Zawitz - MyChesCo
At galera.bet, we promote an agenda of integrity, compliance and - Oficjalny Portal Gminy Brzesko
Oral Mucositis Market expected to rise | Companies- Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics - The Globe and Mail
Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies - MyChesCo
Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 - MyChesCo
Oral Mucositis Market Forecasted to Surge in Coming Years, - openPR
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart
Galera stockholders reject liquidation plan By Investing.com - Investing.com Australia
Galera stockholders reject liquidation plan - Investing.com
Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions - GlobeNewswire Inc.
Take off with Galmed Pharmaceuticals Ltd (GLMD): Get ready for trading - SETE News
Understanding GLMD stock ratios for better investment decisions - US Post News
Genmab A/S (NASDAQ:GMAB) Sets New 52-Week Low at $24.36 - MarketBeat
GLMD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Oral Mucositis Clinical Trials 2024: FDA Approvals, - openPR
Argent Trust Co Purchases New Stake in Globus Medical, Inc. (NYSE:GMED) - Defense World
Mark Bachleda takes the helm at Eyconis - BioCentury
Galmed Pharmaceuticals Calls for Capital Increase Vote - TipRanks
Genmab A/S’s (GMAB) Buy Rating Reiterated at HC Wainwright - Defense World
Market Insights: Galmed Pharmaceuticals Ltd (GLMD)’s Notable Drop of -54.30, Closing at 6.90 - The Dwinnex
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases - StockTitan
Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda - GlobeNewswire
Gossamer Bio shares maintain Buy rating on additional trial data By Investing.com - Investing.com Canada
B. Riley FBR Downgrades Galmed Pharmaceuticals Ltd (GLMD) to a Neutral from a Buy - Knox Daily
Galmed Pharmaceuticals Down 53%, But Still Well Above Monday Closing Price - MarketWatch
Galmed Pharmaceuticals Soars Nearly 500% Amid Nasdaq Compliance and Short Squeeze - TipRanks
Head-To-Head Analysis: Galera Therapeutics (NASDAQ:GRTX) & Galectin Therapeutics (NASDAQ:GALT) - Defense World
Verrica Pharmaceuticals CEO to Present at Global Investment Conference - MyChesCo
Galera Therapeutics Inc Stock (GRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Cap:
|
Volume (24h):